COMMUNIQUÉS West-GlobeNewswire

-
Dyne Therapeutics Secures Up to $275 Million in Debt Financing from Hercules Capital
30/06/2025 -
I-Mab Announces Publication of Givastomig Monotherapy Data in Clinical Cancer Research
30/06/2025 -
Gain Therapeutics Announces Completion of Target Enrollment in Phase 1b Clinical Study Evaluating GT-02287 in People With Parkinson’s Disease With or Without a GBA1 Mutation
30/06/2025 -
Crinetics to Showcase the Next Generation of Endocrinology Innovation at ENDO 2025 with Eight Presentations From its Deep Pipeline
30/06/2025 -
Dyne Therapeutics Announces Proposed Public Offering of Common Stock
30/06/2025 -
INmune Bio, Inc. Announces Closing of Approximately $19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
30/06/2025 -
PetVivo Reports Fiscal 2025 Results
30/06/2025 -
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
30/06/2025 -
Aptose Announces Deferral of Interest Payment
30/06/2025 -
TerrAscend Announces Strategic Exit from Michigan Market
30/06/2025 -
Academy Announces Host, Executive Producer and Author Andy Cohen as 2025 FNCE® Closing Keynote Speaker
30/06/2025 -
Algernon Announces Amended Terms for Private Placement and Closing of the First Tranche totaling $621,000
30/06/2025 -
Avicanna Announces Results of Annual General Meeting
30/06/2025 -
Thought Leadership & Innovation Foundation Releases White Paper Showcasing Model for Non-Profit Collaboration to Improve Outcomes for Chronic Disease Communities
30/06/2025 -
Total number of shares and voting rights in Zealand Pharma as of June 30, 2025
30/06/2025 -
Mineralys Therapeutics Announces Journal of the American Medical Association (JAMA) Publication of Pivotal Phase 3 Launch-HTN Trial for Lorundrostat
30/06/2025 -
Portal Biotech Raises $35 Million Series A, Leveraging AI to Deliver the World’s First Full-Length Single-Molecule Protein Sequencer
30/06/2025 -
Erdem Hospital Launches New Pre-Surgery Education Program for Bariatric Patients
30/06/2025 -
EUROAPI cède le site de Haverhill à Particle Dynamics dans le cadre du plan de transformation FOCUS-27
30/06/2025
Pages